Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H1 2015

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H1 2015', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Bile Duct Cancer (Cholangiocarcinoma) Overview 8

Therapeutics Development 9

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma)-Overview 9

Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma)-Comparative Analysis 10

Bile Duct Cancer (Cholangiocarcinoma)-Therapeutics under Development by Companies 11

Bile Duct Cancer (Cholangiocarcinoma)-Therapeutics under Investigation by Universities/Institutes 15

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Bile Duct Cancer (Cholangiocarcinoma)-Products under Development by Companies 19

Bile Duct Cancer (Cholangiocarcinoma)-Products under Investigation by Universities/Institutes 22

Bile Duct Cancer (Cholangiocarcinoma)-Companies Involved in Therapeutics Development 23

4SC AG 23

Agios Pharmaceuticals, Inc. 24

Ariad Pharmaceuticals, Inc. 25

ArQule, Inc. 26

Array BioPharma Inc. 27

Arrien Pharmaceuticals, LLC 28

AstraZeneca PLC 29

Bayer AG 30

Boston Biomedical, Inc. 31

Bristol-Myers Squibb Company 32

Celgene Corporation 33

CellAct Pharma GmbH 34

Concordia Healthcare Corp. 35

Cornerstone Pharmaceuticals, Inc. 36

Delcath Systems, Inc. 37

Eli Lilly and Company 38

Exelixis, Inc. 39

F. Hoffmann-La Roche Ltd. 40

GlaxoSmithKline Plc 41

Komipharm International Co., Ltd. 42

Mebiopharm Co., Ltd. 43

Merck & Co., Inc. 44

Merrimack Pharmaceuticals, Inc. 45

Novartis AG 46

NuCana BioMed Limited 47

OncoTherapy Science, Inc. 48

Panacea Pharmaceuticals, Inc. 49

PCI Biotech AS 50

Pfizer Inc. 51

Provecs Medical GmbH 52

Sanofi 53

Senhwa Biosciences, Inc. 54

Spectrum Pharmaceuticals, Inc. 55

Threshold Pharmaceuticals, Inc. 56

VasGene Therapeutics, Inc. 57

Bile Duct Cancer (Cholangiocarcinoma)-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Combination Products 59

Assessment by Target 60

Assessment by Mechanism of Action 63

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

(dabrafenib mesylate + trametinib dimethyl sulfoxide)-Drug Profile 70

AG-120-Drug Profile 72

ARN-5032-Drug Profile 74

ARQ-087-Drug Profile 75

BBI-503-Drug Profile 76

BGJ-398-Drug Profile 78

binimetinib-Drug Profile 79

cabozantinib s-malate-Drug Profile 84

CAP-7.1-Drug Profile 87

CC-90007-Drug Profile 89

CPI-613-Drug Profile 92

dasatinib-Drug Profile 94

DKN-01-Drug Profile 97

elpamotide-Drug Profile 99

evofosfamide-Drug Profile 101

gemcitabine hydrochloride-Drug Profile 109

Im-01-Drug Profile 110

KML-001-Drug Profile 111

MBPY-005-Drug Profile 113

melphalan-Drug Profile 114

merestinib-Drug Profile 116

MK-2206-Drug Profile 117

NUC-1031-Drug Profile 120

OCVC-01-Drug Profile 122

paclitaxel albumin bound-Drug Profile 123

PAN-622-Drug Profile 127

pembrolizumab-Drug Profile 128

ponatinib hydrochloride-Drug Profile 135

porfimer sodium-Drug Profile 137

Recombinant Protein to Antagonize EphB4 Receptor for Oncology-Drug Profile 138

refametinib-Drug Profile 140

regorafenib-Drug Profile 143

resminostat-Drug Profile 146

RRX-001-Drug Profile 151

SAR-408701-Drug Profile 153

selumetinib sulfate-Drug Profile 154

seribantumab-Drug Profile 157

silmitasertib-Drug Profile 160

SPI-1620-Drug Profile 162

sunitinib malate-Drug Profile 163

trametinib dimethyl sulfoxide-Drug Profile 167

Vaccine for Metastatic Cholangiocarcinoma-Drug Profile 170

vemurafenib-Drug Profile 171

Bile Duct Cancer (Cholangiocarcinoma)-Recent Pipeline Updates 174

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects 253

Bile Duct Cancer (Cholangiocarcinoma)-Discontinued Products 255

Bile Duct Cancer (Cholangiocarcinoma)-Product Development Milestones 256

Featured News & Press Releases 256

Appendix 264

Methodology 264

Coverage 264

Secondary Research 264

Primary Research 264

Expert Panel Validation 264

Contact Us 264

Disclaimer 265

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015 12

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by 4SC AG, H1 2015 26

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 27

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Ariad Pharmaceuticals, Inc., H1 2015 28

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by ArQule, Inc., H1 2015 29

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Array BioPharma Inc., H1 2015 30

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 31

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by AstraZeneca PLC, H1 2015 32

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Bayer AG, H1 2015 33

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Boston Biomedical, Inc., H1 2015 34

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Bristol-Myers Squibb Company, H1 2015 35

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Celgene Corporation, H1 2015 36

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by CellAct Pharma GmbH, H1 2015 37

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Concordia Healthcare Corp., H1 2015 38

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 39

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Delcath Systems, Inc., H1 2015 40

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Eli Lilly and Company, H1 2015 41

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Exelixis, Inc., H1 2015 42

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 43

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by GlaxoSmithKline Plc, H1 2015 44

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Komipharm International Co., Ltd., H1 2015 45

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Mebiopharm Co., Ltd., H1 2015 46

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Merck & Co., Inc., H1 2015 47

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 48

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Novartis AG, H1 2015 49

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by NuCana BioMed Limited, H1 2015 50

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by OncoTherapy Science, Inc., H1 2015 51

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 52

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by PCI Biotech AS, H1 2015 53

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Pfizer Inc., H1 2015 54

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Provecs Medical GmbH, H1 2015 55

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Sanofi, H1 2015 56

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Senhwa Biosciences, Inc., H1 2015 57

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 58

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 59

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by VasGene Therapeutics, Inc., H1 2015 60

Assessment by Monotherapy Products, H1 2015 61

Assessment by Combination Products, H1 2015 62

Number of Products by Stage and Target, H1 2015 64

Number of Products by Stage and Mechanism of Action, H1 2015 67

Number of Products by Stage and Route of Administration, H1 2015 70

Number of Products by Stage and Molecule Type, H1 2015 72

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics-Recent Pipeline Updates, H1 2015 177

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects, H1 2015 256

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects (Contd..1), H1 2015 257

Bile Duct Cancer (Cholangiocarcinoma)-Discontinued Products, H1 2015 258

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2015 12

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 20

Assessment by Monotherapy Products, H1 2015 61

Number of Products by Top 10 Targets, H1 2015 63

Number of Products by Stage and Top 10 Targets, H1 2015 63

Number of Products by Top 10 Mechanism of Actions, H1 2015 66

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 66

Number of Products by Top 10 Routes of Administration, H1 2015 69

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70

Number of Products by Top 10 Molecule Types, H1 2015 71

Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

Agios Pharmaceuticals, Inc.

Ariad Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma Inc.

Arrien Pharmaceuticals, LLC

AstraZeneca PLC

Bayer AG

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

CellAct Pharma GmbH

Concordia Healthcare Corp.

Cornerstone Pharmaceuticals, Inc.

Delcath Systems, Inc.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Komipharm International Co., Ltd.

Mebiopharm Co., Ltd.

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Novartis AG

NuCana BioMed Limited

OncoTherapy Science, Inc.

Panacea Pharmaceuticals, Inc.

PCI Biotech AS

Pfizer Inc.

Provecs Medical GmbH

Sanofi

Senhwa Biosciences, Inc.

Spectrum Pharmaceuticals, Inc.

Threshold Pharmaceuticals, Inc.

VasGene Therapeutics, Inc.

Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Products under Development, Key Players in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Bile Duct Cancer (Cholangiocarcinoma) Pipeline Overview, Bile Duct Cancer (Cholangiocarcinoma) Pipeline, Bile Duct Cancer (Cholangiocarcinoma) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com